The announcement of new quantitative PET imaging data on Foralumab by Tiziana Life Sciences at a prestigious meeting suggests positive progress in their research. This could lead to increased investor confidence and potential appreciation in stock value in the short term, as it indicates forward momentum in product development and potential future regulatory approvals.